A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinryze (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-mediated Rejection in Kidney Transplant Patients

Trial Profile

A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinryze (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-mediated Rejection in Kidney Transplant Patients

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Complement C1 inhibitor protein (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Shire
  • Most Recent Events

    • 11 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 15 Dec 2015 According to a Shire media release, Shire plans to initiate this study in 2016.
    • 15 Dec 2015 Planned initiation date changed from 1 Oct 2015 to 1 Jan 2016 according to a Shire media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top